SVB Leerink Maintains Outperform on Molecular Partners, Lowers Price Target to $35
SVB Leerink analyst Daina Graybosch maintains Molecular Partners (NASDAQ:MOLN) with a Outperform and lowers the price target from $36 to $35.
Earnings Scheduled For August 26, 2021
Companies Reporting Before The Bell
• Gambling.com Gr (NASDAQ:GAMB) is likely to report quarterly earnings at $0.07 per share on revenue of $10.38 million.
AbbVie Returns Eye Drug Candidate To Molecular Partners
AbbVie Inc (NYSE: ABBV) has terminated its license and colla
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.
Molecular Partners – Novartis’ COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant
Molecular Partners AG (NASDAQ:MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with…
The Daily Biotech Pulse: Iterum’s Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 28)
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.